Marshall Wace’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-223,353
| Closed | -$833K | – | 2946 |
|
|
2024
Q3 | $833K | Buy |
223,353
+27,878
| +14% | +$104K | ﹤0.01% | 1593 |
|
|
2024
Q2 | $1.09M | Sell |
195,475
-61,994
| -24% | -$347K | ﹤0.01% | 1491 |
|
|
2024
Q1 | $1.35M | Buy |
257,469
+113,643
| +79% | +$595K | ﹤0.01% | 1333 |
|
|
2023
Q4 | $752K | Buy |
+143,826
| New | +$752K | ﹤0.01% | 1307 |
|
|
2023
Q2 | – | Sell |
-65,967
| Closed | -$1.87M | – | 2697 |
|
|
2023
Q1 | $1.87M | Buy |
65,967
+50,691
| +332% | +$1.44M | ﹤0.01% | 1188 |
|
|
2022
Q4 | $447K | Buy |
+15,276
| New | +$447K | ﹤0.01% | 1851 |
|
|
2021
Q2 | – | Sell |
-23,449
| Closed | -$979K | – | 2672 |
|
|
2021
Q1 | $979K | Buy |
+23,449
| New | +$979K | ﹤0.01% | 1405 |
|
|
2019
Q4 | – | Sell |
-51,590
| Closed | -$2.92M | – | 2089 |
|
|
2019
Q3 | $2.92M | Buy |
51,590
+16,040
| +45% | +$907K | 0.02% | 619 |
|
|
2019
Q2 | $1.98M | Sell |
35,550
-14,638
| -29% | -$815K | 0.02% | 746 |
|
|
2019
Q1 | $2.53M | Sell |
50,188
-61,276
| -55% | -$3.09M | 0.02% | 661 |
|
|
2018
Q4 | $4.49M | Buy |
+111,464
| New | +$4.49M | 0.05% | 474 |
|
|
2018
Q2 | – | Sell |
-4,300
| Closed | -$227K | – | 870 |
|
|
2018
Q1 | $227K | Buy |
+4,300
| New | +$227K | 0.01% | 505 |
|
|
2015
Q3 | – | Sell |
-47,509
| Closed | -$3.84M | – | 1087 |
|
|
2015
Q2 | $3.84M | Buy |
+47,509
| New | +$3.84M | 0.05% | 337 |
|